A5066236327- Platelet Disorders and Treatments
- Venous Thromboembolism Diagnosis and Management
- Neutropenia and Cancer Infections
- Blood groups and transfusion
- Chronic Lymphocytic Leukemia Research
- Hemophilia Treatment and Research
- Cancer Treatment and Pharmacology
- Heparin-Induced Thrombocytopenia and Thrombosis
- Multiple Myeloma Research and Treatments
- Atrial Fibrillation Management and Outcomes
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Central Venous Catheters and Hemodialysis
- Sepsis Diagnosis and Treatment
- Hemostasis and retained surgical items
- Blood Coagulation and Thrombosis Mechanisms
- Antiplatelet Therapy and Cardiovascular Diseases
- Hematological disorders and diagnostics
- Chemotherapy-induced cardiotoxicity and mitigation
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Blood transfusion and management
- Fetal and Pediatric Neurological Disorders
- Complement system in diseases
- Endometrial and Cervical Cancer Treatments
Memorial Sloan Kettering Cancer Center
2012-2022
Cornell University
2012-2020
Michigan State University
2011
St. Elizabeth's Medical Center
2008-2010
Tufts University
2008-2010
Indiana Hemophilia and Thrombosis Center
2003-2006
Royal London Hospital
2000
This study was designed to determine the incidence of venous and arterial thromboembolic events (TEEs) in patients treated with cisplatin-based chemotherapy analyze prognostic value patients' baseline treatment characteristics predicting TEE occurrence.We performed a large retrospective analysis all for any type malignancy at Memorial Sloan-Kettering Cancer Center 2008. A cisplatin-associated if it occurred between time first dose cisplatin 4 weeks after last dose.Among 932 patients, 169...
Summary. Recombinant activated factor VII (rFVIIa), licensed in 1999 for treatment of haemophilia patients with inhibitors (HI), represents an important advance the therapeutic armamentarium. Standard bolus dosing ranges from 90 to 120 mcg kg −1 every 2–3 h until arrest bleeding. As licensure, clinical use rFVIIa has increased and broadened. Clinicians now a wide dose range, 90–300 . High‐dose regimens may optimize thrombin generation or burst, allow prolonged interval. The Hemophilia...
Low-molecular weight heparin (LMWH) has been the standard of care for treatment venous thromboembolism (VTE) in patients with cancer. Rivaroxaban was approved 2012 pulmonary embolism (PE) and deep vein thrombosis (DVT), but no prior studies have reported specifically evaluating efficacy safety rivaroxaban cancer-associated (CAT). Under a Quality Assessment Initiative (QAI), we established Clinical Pathway to guide use CAT now report validation analysis our first 200 patients. A patient...
Chemotherapy-induced thrombocytopenia (CIT) leads to delay or reduction in cancer treatment. There is no approved treatment.We conducted a phase II randomized trial of romiplostim versus untreated observation patients with solid tumors CIT. Before enrollment, had platelets less than 100,000/μL for at least 4 weeks, despite dose chemotherapy. Patients received weekly titrated target platelet count more, were monitored usual care. The primary end point was correction within 3 weeks....
The development of thrombocytopenia in the setting therapeutic anticoagulation for venous thromboembolic disease (VTE) is common cancer patients, but guidelines management are based on limited past data and have not been validated. In 2011, Memorial Sloan Kettering Cancer Center (MSKCC) implemented following this setting: administer full dose enoxaparin a platelet count > 50,000/mcL, half-dose 25,000-50,000/mcL, hold < 25,000/mcL. We now report validation safety efficacy these guidelines. As...
Abstract Background Neutropenia is commonly encountered in cancer patients. Recombinant human granulocyte colony-stimulating factor (G-CSF, filgrastim), a cytokine that initiates proliferation and differentiation of mature granulocytes, widely given to oncology patients counteract neutropenia, reducing susceptibility infection. However, the clinical impact neutropenia G-CSF use with coronavirus disease 2019 (COVID-19) remains unknown. Methods An observational cohort 379 actively treated...
OBJECTIVE: To estimate the incidence of postoperative venous thromboembolism among patients undergoing minimally invasive surgery for endometrial cancer, and to characterize risk factors associated with development thromboembolism. METHODS: Patients newly diagnosed cancer who were scheduled undergo a planned procedure from May 1, 2007 December 31, 2010 identified. The symptomatic was estimated in did not require conversion laparotomy. Various clinicopathologic variables tested an association...
Patients with hematologic malignancies are at risk for severe thrombocytopenia (sTP). The and benefit of aspirin not known in thrombocytopenic cancer patients experiencing acute myocardial infarction (AMI).Medical records diagnosed AMI Memorial Sloan Kettering Cancer Center during 2005-2014 were reviewed. sTP was defined as a platelet count <50,000 cells per µL within 7 days AMI.Of 118 who had AMI, 58 (49%) sTP. Twenty-five (43%) received treatment AMI. Compared without less likely to...
Congenital afibrinogenaemia and hypofibrinogenaemia are rare disorders of haemostasis. In this case report the problems posed in management two patients with fibrinogen levels less than 0.1g L(-1) who developed intracranial bleeding considered. The value concentrate role prophylaxis is also discussed.
Background Neutropenia is commonly encountered in cancer patients, and recombinant human granulocyte colony-stimulating factor (G-CSF, filgrastim) widely given to oncology patients counteract neutropenia prevent infection. G-CSF both a growth cytokine that initiates proliferation differentiation of mature granulocytes. However, the clinical impact use who are also afflicted with coronavirus disease 2019 (COVID-19), remains unknown. Methods An observational cohort 304 hospitalized COVID-19 at...
Immune thrombocytopenia (ITP) is frequently encountered in patients with lymphoproliferative disorders. However this only rarely reported multiple myeloma. We describe three cases who presented initially the clinical manifestations of ITP but were subsequently found to have Platelet count increments standard treatment modalities for observed all transient or partial response. The importance recognizing immune mediated myeloma and implications combination are discussed.
We report the results of a non-randomized pilot study an oral regimen comprising CCNU (lomustine; 25 or 50 mg/m2 on day 1), idarubicin (4-demethoxydaunorubicin) (10 days 1-3) and dexamethasone mg b.d. 1-4) in patients with relapsed refractory myeloma. Treatment was given every 28 d for maximum six courses. Sixty were entered whom 57 evaluable. Overall response rate (partial minor response) 49% 30% achieving partial (50% tumour reduction). Response rates higher untested relapse than those...
Summary. The aim of this study was to characterize the adequacy and longevity biological response desmopressin (DDAVP) in a large Amish kindred Type 2M von Willebrand disease (VWD) possessing C‐to‐T transition at nucleotide 4120 exon 28 A1 domain factor (VWF) gene. Response both intranasal (Stimate ® ) subcutaneous DDAVP administration assessed. Rise ristocetin cofactor activity (VWF:RCo) ≥ 40% 90‐min post‐Stimate 1–2 h after defined as initial response; assessed only dosing by measuring...
Acquired factor VIII deficiency is a rare entity that can lead to severe and life-threatening bleeding. We describe case of bleeding from the tongue secondary acquired hemophilia discuss treatment options, including aminocaproic acid recombinant VIII, which have not been widely reported in literature for management such patients.A 94-year-old Caucasian man presented our institution with diffuse bruising extensive mechanical trauma. He had no prior history his medical was unremarkable except...